Avalo doses first patient in Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa

Avalo Therapeutics, Inc.

Phase 2 LOTUS trial enrolling ~180 adults with moderate to severe hidradenitis suppurativa.
Two dose regimens of AVTX-009 vs placebo in 1:1:1 randomization over 16-week treatment phase.
Primary endpoint: proportion achieving HiSCR75 at Week 16; topline data expected in 2026.
CEO Garry Neil cited high potency potential for best-in-class treatment option.
AVTX-009 is a humanized monoclonal antibody targeting IL-1β with high affinity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.